



Vicente Ortún
October 5th, 2009



The Merck Company Foundation Program on Pharmaceutical Policy Issues

Ph. D. dissertations directed by CRES members, Universitat Pompeu Fabra
in the framework of the research grant awarded by the Merck Foundation
to the University Carlos III from Madrid and
the University Pompeu Fabra from Barcelona

Pedro Cervera, Pharmacist. Bridging the quality gap on drug utilization. *Ph.D. dissertation at Alicante University*. Directed by S Peiró, B González and J Puig-Junoy. *Expected 2010*. Articles already finished:

- Peiró S, Cervera P, Sanfélix G, Librero J. Recent trends in gastrointestinal bleeding in the Valencia region. Relationship to sales on nonsteroidal anti-inflammatory drugs and acid suppression medication. An ecological study. *Pharmacoepidemiology & Drug Safety* 2009, *in press*.
- Sanfélix-Gimeno G, Cervera P, Peiró S, González López-Valcárcel B. Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs. An interrupted time-series analysis in Spain. *Drug Safety* 2009; 32(11): 1-13.
- Cervera P, Peiró S, Sanfélix-Gimeno G. Decline in use of hormone replacement therapy in the Valencia Community after adverse results from clinical trials. An interrupted time-series analysis. 2008, *under review*.
- Peiró S, Cervera P. The effectiveness of pharmaceutical intervention on the appropriateness and efficiency of drug utilization. 2008, *under review*.

Desogus C, *Ph.D. candidate Bologna University*. While at CRES-UPF, she wrote part of her dissertation: Antitrust issues in the Euro trade, 2009

Laura Diego del Río, Pharmacist at CedimCat. Determinants of the velocity of incorporation of therapeutic novelties to the clinical practice. Directed by V Ortún. Universitat Pompeu Fabra, expected 2011.

Anna Garcia-Altés, now, senior lecturer, joint appointment King's College and London School of Economics. Essays on health capital and the efficiency of health care. Directed by V Ortún. Universitat Autònoma de Barcelona, November 2008.

Ana Merino, now at Catalonia's Anti-Trust Authority. The demand for pharmaceutical drugs under the new regulatory framework: a theoretical and empirical approach. Universitat Pompeu Fabra, 2003. Directed by J Puig-Junoy.

Jorge Mestre Ferrándiz, now at the Office of Health Economics, London. Thesis title: 'Essays on Regulatory Aspects of the European pharmaceutical market: an economic analysis of recent cases on parallel Pharmaceutical Industry'. Universitat Autònoma de Barcelona, 1992.

Ivan Moreno, Assistant professor at UPF. Essays on the Analysis of Pharmaceutical Industry Competition Policy. Directed by J Puig Junoy, Universitat Pompeu Fabra, and JR Borrell, Universitat de Barcelona. Articles already finished:

- Moreno I, Puig-Junoy J, Borrell JR. Generic Entry into the Regulated Spanish Pharmaceutical Market. *Review of Industrial Organization* 2009; 34: 373-88.
- Puig-Junoy J, Moreno I. Impact of Pharmaceutical Prior Authorization Policies: A Systematic Review of the Literature. *Pharmacoeconomics* 2007; 25(8): 637-648.

- Moreno I. Product-line extension as a competitive tool in a regulated pharmaceutical market. *Planned for 2009.*

Silvia Ondategui Parra, now Director of Health Affairs at Price Waterhouse and Coopers and Lybrand, Spain. Performance indicators in academic radiology departments in the United States. Directed by V Ortún. Universitat Pompeu Fabra, Barcelona, April 2008.

Gabriel Sanfélix Gimeno, Centro Superior de Investigación en Salud Pública. Valencia. Variaciones en el consumo y gasto de medicamentos empleados en la hipertensión arterial en la Comunidad Valenciana. Directed by S Peiró and JM Aranz, 2009.

Anna Tur, Assistant professor at UPF. Essays on pharmaceutical policy issues. Directed by J Puig-Junoy, Universitat Autònoma de Barcelona. The Impact of Co-payment exemption on Pharmaceutical Consumption: Evidence from Spain. *First article of Ana's PhD dissertation at Universitat Autònoma de Barcelona, 2009.*